Why this ASX cannabis share zoomed 9% higher today

The Elixinol Global Ltd (ASX:EXL) share price jumped 9% higher on Thursday despite posting a $83.5 million full year loss…

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Elixinol Global Ltd (ASX: EXL) share price is pushing higher on Thursday despite it announcing an $83.5 million full year loss.

In afternoon trade the cannabis company's shares are up 3.5% to 44.5 cents. They were up 9% at one stage to 47 cents.

How did Elixinol Global perform in FY 2019?

For the 12 months ended December 31, Elixinol reported a 16% year on year decline in revenue from continuing operations to $27.2 million.

Management advised that this was due to a 34% decline in bulk sales due to the influx of cheap, poor quality product and a 56% decline in private label sales due to the termination of low margin private label contracts.

One positive was that the company delivered a 35% increase in high margin Elixinol branded and co-branded product sales during the 12 months. Elixinol branded product sales now represent 59% of total revenue, up from 37% in FY 2018.

The company's continuing operations reported an EBITDA loss of $22.9 million and a loss after tax of $83.5 million. This reflects non-cash asset impairment charges of $48.8 million due to a reset of expectations. These include $39.4 million goodwill and $8.4 million for excess inventory provisions.

Elixinol had cash and cash equivalents of $20.4 million at the end of the period.

Management commentary.

Elixinol's CEO, Stratos Karousos, was pleased with the performance of Elixinol branded products in FY 2019, but acknowledged that its overall performance was disappointing in the second half.

He said: "It's pleasing to see sales of Elixinol branded products have increased 35% in FY2019. This highlights Elixinol's leadership team are executing on our refined strategy of focusing on high margin Elixinol branded hemp-derived CBD products. Although revenues in Q3 and Q4 FY2019 were disappointing, we undertook swift action to divest non-core assets and simplify the business model."

Mr Karousos appears confident that its cash burn rate will improve greatly in the future.

He added: "With a continued focus on cost control and the execution of various working capital reduction initiatives, the future quarterly cash burn rate is planned to be lower than historical run rates. Additionally, our operating budget, which is not predicated upon regulatory development in the US and Europe & UK, provides a pathway towards positive cashflow and increased gross margins."

Outlook.

No guidance was provided for FY 2020, but management appears optimistic thanks to new product launches.

Mr Karousos said: "I am excited about our total brand refresh which will be launched in March 2020. Our Elixinol branded product range has been optimised to suit customer demands and we have a pipeline of new and innovative products which will be launched during 2020."

"We will continue to focus on return on investment to enable the company to leverage the significant capital that has been deployed in operations, eCommerce, raw materials and key people. Elixinol's refined strategy on hemp derived CBD in the US, Europe & UK ensures Elixinol is well positioned to grow its high margin branded products, despite prolonged regulatory developments, with a pathway to positive cashflows and will be able to capitalise on the expected global growth in the hemp derived CBD market in 2020 and beyond," he concluded.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

A happy young couple lie on a wooden deck using a skateboard for a pillow.
Share Gainers

These were the best-performing ASX 200 shares in March

These shares made their shareholders smile in March thanks to some very big gains.

Read more »

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
Share Gainers

3 ASX All Ords shares up 50%+ in March

These ASX shares have been on fire this month. But why?

Read more »

Woman looks amazed and shocked as she looks at her laptop.
Share Gainers

Why Mesoblast, Patriot Battery Metals, Sigma, and Zip shares are pushing higher

These shares are having a good session on hump day. But why?

Read more »

Woman looks amazed and shocked as she looks at her laptop.
Consumer Staples & Discretionary Shares

If you'd put $20,000 in this ASX retail stock at the start of 2023, you'd have $134,000 now

This online retailer has executed a remarkable turnaround for its investors.

Read more »

Fancy font saying top ten surrounded by gold leaf set against a dark background of glittering stars.
Share Gainers

Here are the top 10 ASX 200 shares today

It was back to earth for ASX shares this Tuesday.

Read more »